Scott A. Schaller, Ph.D. is counsel in Sterne Kessler’s Biotechnology & Chemical Practice Group. Scott has extensive experience in the preparation and prosecution of U.S. and foreign patent applications. Scott also counsels and assists domestic and international clients regarding strategic patent planning of complex portfolios as well as issues relating to patentability, freedom-to-operate, due diligence, validity, and infringement analyses and opinions. His practice areas include biotechnology, pharmaceuticals, chemicals, and therapeutic antibodies.

Scott is a contributing author of Patent Office Litigation, a two-volume set focused on the new contested proceedings under the America Invents Act published in 2012 by Thomson Reuters Westlaw. This book examines how the proceedings interact with other aspects of patent procurement and enforcement, and delivers practical analysis and advice.

Scott earned his B.S. in molecular biology and biochemistry with the highest honors from the University of Southern Mississippi. He received his J.D. from The University of Texas School of Law with honors, and earned his Ph.D. in molecular and cellular biology from Tulane University. During his graduate studies, Scott’s research focused on the molecular and cellular mechanisms underlying pattern formation in the developing vertebrate limb during embryogenesis. His technical expertise includes molecular and cellular biology, biochemistry, immunology, and virology.

  • J.D., The University of Texas School of Law, with honors
  • Ph.D., Molecular and Cellular Biology, Tulane University
  • B.S., Molecular Biology and Biochemistry, University of Southern Mississippi, with highest honors

  • District of Columbia
  • Georgia
  • Texas
  • United States Patent & Trademark Office

  • American Bar Association
  • American Intellectual Property Law Association

Related News & Insights

From Scott A. Schaller, Ph.D.


March 9, 2022

The CREATE Act of 2004: Observations and Open Issues After 18 Years

Westlaw Today Eric K. Steffe, Scott A. Schaller, Ph.D.

In the News

June 2, 2020

Amgen Drops Alexion Blood Drug IPRs, Gets 2025 License



March 27, 2015

IP Flash: Transformative Subject Matter Patent-Eligibility in the US

European Biotechnology Scott A. Schaller, Ph.D.


January 15, 2013

After Alice: The Two-Step Rule

LSIPR Newsletter Scott A. Schaller, Ph.D.

Books and Chapters

January 1, 2012

Patent Office Litigation

Thomson Reuters Westlaw Multiple Authors